ASCRS•ASOA SYMPOSIUM & CONGRESS, SAN FRANCISCO
In the "Update on Corneal Collagen Crosslinking" session, Doyle Stulting, MD, discussed
some of the complications involved with crosslinking.
said. This affects the regulatory
pathway. Crosslinking is available in
numerous other countries but not in
the U.S.
She said the clinical trial process
is one of the biggest challenges for
crosslinking in the United States.
One of the reasons there is so much
trouble getting this to market is the
cost. "The estimated cost for getting
the drug to market is somewhere be-
tween 400 million and 1.6 billion
dollars," Ms. Fant said. EW
Editors' note: Dr. Hovanesian has
financial interests with CXLUSA. Dr.
Rubinfeld has financial interests with
CXLO and CXLUSA. Dr. Stulting has
no related financial interests. Ms. Fant
has financial interests in crosslinking
through her company.
EL CONQUISTADOR
a Waldorf Astoria Property
The Premier Innovative Educational Retreat for
Anterior Segment Surgeons and Administrators
Make your advance reservation today.
www.WinterUpdate.org
